Pfizer (NYSE:PFE) Shares Up 0.7%

Pfizer Inc. (NYSE:PFE) shares shot up 0.7% during mid-day trading on Monday . The company traded as high as $26.17 and last traded at $26.05. 11,419,058 shares were traded during mid-day trading, a decline of 73% from the average session volume of 42,392,063 shares. The stock had previously closed at $25.86.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Price Performance

The firm has a market capitalization of $145.47 billion, a PE ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a 50-day simple moving average of $27.23 and a 200-day simple moving average of $28.79.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period last year, the firm posted $1.14 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Pfizer by 4.9% in the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after buying an additional 11,099,024 shares during the period. Moneta Group Investment Advisors LLC raised its stake in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 8.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after buying an additional 8,473,686 shares during the period. Morgan Stanley raised its stake in Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares during the period. Finally, Norges Bank bought a new stake in Pfizer during the 4th quarter valued at approximately $2,129,927,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.